ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 549

Augmented Megakaryopoiesis Supports Accumulation Of Plasma Cells In Lupus-Prone Mice

Oliver Winter1, Niels-Peter Becker2, Stephanie Musiol2, Katrin Moser3, Falk Hiepe4 and Rudolf A. Manz5, 1Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, 2Charité - University Medicine Berlin, Berlin, Germany, 3German Arthritis Research Center (DRFZ Berlin), Berlin, Germany, 4Rheumatology and Clinical Immunology, Charité University Hospital Berlin, Berlin, Germany, 5Institute for Systemic Inflammation Research (ISEF), University of Lübeck, Lübeck, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Lupus and plasma cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Autoantibodies – secreted by short- and long-lived plasma cells in bone marrow and spleen – trigger the immune response, and immune complex deposits in the kidneys can lead to the development of a severe nephritis. As such, autoreactive plasma cells contribute to the pathogenesis of the autoimmune disease Systemic Lupus Erythematosus (SLE). In NZB/W mice – a mouse model for SLE – both parental strains New Zealand Black (NZB) and New Zealand White (NZW) add different sle-loci to the formation of SLE. The NZB strain passes the sle2c locus that contains the gene for the Thrombopoietin (TPO)-receptor (c-mpl). According to the relevance of megakaryocytes for the plasma cell niche and the correlation between plasma cell and megakaryocyte numbers, we wanted to elucidate whether megakaryopoiesis, c-Mpl or c-Mpl signaling is altered in autoimmune mice.

Methods:

We assessed the amount, and cellular environment of megakaryocytes and plasma cells in spleen and bone marrow of wildtype, NZB, NZW and NZB/W mice via flow-cytometry and confocal microscopy. We also investigated the intensity of megakaryopoiesis upon TPO stimulation, the occurrence of genetic variations for c-mpl and the activation of signaling pathways downstream of c-Mpl by in vitro studies, and by gene and protein analysis.

Results:

We found the 10-fold amount of long-lived plasma cells and megakaryocytes in the spleens of NZB mice compared to wildtype, in NZW mice equal numbers, and in NZB/W mice numbers between those for NZB and NZW or wildtype. Furthermore, in the spleen a fraction of plasma cells clustered around megakaryocytes and in vitro megakaryocytes support plasma cell survival. Upon TPO stimulation of splenocyte and bone marrow cultures, NZB megakaryocytes proliferated significantly stronger resulting in the double amount of megakaryocytes compared to NZW cultures. Via sequence analysis we detected a missense mutation in the c-mpl gene of NZB mice leading to an amino acid replacement within the essential TPO-binding site. However, in vitro experiments with wildtype and mutant c-mpl BaF3-clones revealed that this mutation is actually hampering the proliferation upon TPO stimulation and hyperactivation of downstream signals is overcompensating.

Conclusion:

In summary, our data indicate that augmented megakaryopoiesis enables the accumulation of a greater number of autoreactive plasma cells in lupus prone NZB/W mice. Thus, we propose that enhanced megakaryopoiesis and greater megakaryocyte numbers are contributing to the development and/or pathogenesis of SLE.


Disclosure:

O. Winter,
None;

N. P. Becker,
None;

S. Musiol,
None;

K. Moser,
None;

F. Hiepe,
None;

R. A. Manz,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/augmented-megakaryopoiesis-supports-accumulation-of-plasma-cells-in-lupus-prone-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology